Phase 1 Start~month

Phase 1 Start: A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascendin

Indication
Healthy Volunteers

Other upcoming events for RCUS

Phase 2 StartPhase 2 Start: PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOS
Phase 3 ReadoutPhase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib
Patent ExpiryPatent/Exclusivity Expiry: PEMETREXED

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 1 Start: A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascendin — RCUS Phase 1 Start | BioSniper